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Newly-emerged and vaccine-mismatched inﬂuenza A viruses (IAVs) result in a rapid global
spread of the virus due to minimal antibody-mediated immunity. In that case, established
CD8+ T-cells can reduce disease severity. However, as mutations occur sporadically within
immunogenic IAV-derived T-cell peptides, understanding of T-cell receptor (TCRαβ) cross-
reactivity towards IAV variants is needed for a vaccine design. Here, we investigate TCRαβ
cross-strain recognition across IAV variants within two immunodominant human IAV-
speciﬁc CD8+ T-cell epitopes, HLA-B*37:01-restricted NP338-346 (B37-NP338) and HLA-
A*01:01-restricted NP44-52 (A1-NP44). We ﬁnd high abundance of cross-reactive TCRαβ
clonotypes recognizing distinct IAV variants. Structures of the wild-type and variant peptides
revealed preserved conformation of the bound peptides. Structures of a cross-reactive TCR-
HLA-B37-NP338 complex suggest that the conserved conformation of the variants underpins
TCR cross-reactivity. Overall, cross-reactive CD8+ T-cell responses, underpinned by con-
served epitope structure, facilitates recognition of distinct IAV variants, thus CD8+ T-cell-
targeted vaccines could provide protection across different IAV strains.
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Inﬂuenza A viruses (IAVs) rapidly evolve and cause signiﬁcantmorbidity and mortality (reviewed in refs. 1,2). Annual epi-demics are responsible for >500,000 deaths worldwide3, while
pandemics can cause >50 million deaths (reviewed in ref. 4).
Although vaccines are available, they primarily induce neu-
tralizing antibodies directed towards the rapidly mutating surface
glycoproteins, rather than cross-reactive CD8+ T cell
immunity1,5, mandating that these vaccines are updated and
administered annually (reviewed in ref. 6). Furthermore, these
vaccines are fallible when the circulating strains do not match the
predicted vaccine strains7 or in a scenario when a novel viral
subtype enters the population. Thus there is an urgent need to
understand correlates of T cell protection towards IAV to provide
effective inﬂuenza vaccine design.
In the absence of neutralizing antibodies, strain cross-reactive
CD8+ T cells can protect against IAVs. Murine studies show that
CD8+ T cells correlate with decreased morbidity and mortality
following IAV infection8–12 and can provide protection during
infection with heterosubtypic IAV strains11,13–15. Human studies
are consistent with murine data. Namely, published evidence
shows that prominence of inﬂuenza-speciﬁc CD8+ T cells cor-
relates with lower viral titers16 and decreased disease severity17–19
during IAV infection. Furthermore, CD8+ T cells primed with
seasonal circulating IAV strains can cross-react with pandemic
H1N1 (pH1N1) or variant seasonal peptides20–22 or virulent
H7N9 and H5N1 avian IAV-derived peptides23–26. Together,
these data suggest that an IAV-speciﬁc CD8+ T cell-mediated
vaccine can provide broad cross-reactive immunity across distinct
inﬂuenza A strains and subtypes for both conserved and variable
CD8+ T cell epitopes.
It is well established that CD8+ T cells with diverse T cell
receptor (TCR) repertoires are greatly beneﬁcial for disease out-
come, contributing to reduced disease severity27, enhanced CD8+
T cell function28, cross-reactivity across different peptide
variants29,30, and preventing viral escape31,32. Importantly,
although CD8+ TCRs are typically highly speciﬁc for their cog-
nate peptide, they can also recognize a broad range of peptide
variants, thus allowing CD8+ T cells to have a powerful capacity
to recognize not only their cognate peptide but also a range of
viral mutants11,30,33–36. In case of highly mutating inﬂuenza
viruses, such cross-reactive CD8+ T cells are highly desirable as
they elicit immune responses towards multiple viral strains and
hence provide cross-strain protection.
The precise mechanisms underlying cross-recognition by
inﬂuenza-speciﬁc CD8+ TCRs in humans are unclear. To date,
TCRαβ repertoires have only been dissected for two immuno-
dominant inﬂuenza-speciﬁc human epitopes, HLA-A*02:01-
restricted M15830 and HLA-B*35:01/*35:03/*07:02-restricted
NP41830, providing ∼50% of the cumulative population coverage.
Thus it is important to understand cross-reactivity and diversity
of CD8+ T cell TCRαβ repertoires directed against other pro-
minent IAV-speciﬁc epitopes, if we are to rationally design a
broadly protective CD8+ T cell-mediated inﬂuenza vaccine.
Here we use an ex vivo multiplex reverse transcription poly-
merase chain reaction (RT-PCR) approach30,37,38 to analyze
paired TCRαβ repertoires for two additional prominent human
CD8+ T cell epitopes, HLA-B*37:01-restricted NP338–346-
FEDLRVLSF (NP338)39 and HLA-A*01:01-restricted NP44–52
CTELKLSDY (NP44)23,40, restricted by alleles that are frequent in
the human population (∼19% of the cumulative coverage). We
identify cross-reactive TCRαβ clonotypes capable of recognizing
the wild-type (WT) peptide and peptide variants. This is most
prominent in HLA-B*37:01-expressing donors, where distinct
and cross-reactive NP338-speciﬁc TCRαβ clonotypes bound each
of the NP338-WT, NP338-L7S, and NP338-V6L variants (93–100%
of distinct IAV strains), highlighting their potential to provide
protection against distinct inﬂuenza strains and subtypes. Our
structural analysis reveals that the variants adopt a similar con-
formation than the WT epitope for both HLA-A*01:01 (HLA-A1)
and HLA-B*37:01 (HLA-B37) molecules, providing a molecular
basis for CD8+ TCRαβ cross-reactivity. Structural analysis indi-
cates that molecular similarity may underpin how an HLA-B37-
restricted cross-reactive TCRαβ, clone EM2, can recognize the
variants. Thus our data suggest that structural resemblance
underpins cross-reactivity of HLA-B37+NP338+CD8+ and HLA-
A1+NP44+CD8+ T cells, despite their diverse TCR repertoires
between individuals towards those two epitopes.
Results
Only HLA-B37+ donors elicit a NP388+CD8+ T cell response.
Our previous work identiﬁed NP338 as an immunodominant CD8
+ T cell epitope in individuals expressing HLA-B3739. However,
NP338 was previously reported to be restricted by HLA-B*44:0341.
Thus we ﬁrst investigated whether the NP338 peptide can be
presented by other HLA allomorphs using the online SYFPETHI
peptide-binding prediction tool42. A high prediction binding score
for the NP338 peptide was obtained for HLA-B37, HLA-B*44:02,
and HLA-B*18:01 (HLA-B18) (Table 1). The SYFPETHI website
contains only the HLA-B*44:02 in its database but not the closely
related allomorphs, such as HLA-B*44:03 and HLA-B*44:0543.
The high prediction binding score for the NP338 peptide obtained
for HLA-B*44:02 is likely to be shared by HLA-B*44:03 and HLA-
B*44:05 (HLA-B44), given their known overlapping peptide
repertoire44. Both HLA-B4444–47 and HLA-B1846,48 display a
preference for P2-E and PΩ-F/Y in their bound peptides, and both
residues are present in the IAV-derived NP338 peptide.
We ﬁrst refolded the NP338 peptide with HLA-B37, HLA-B18,
and HLA-B44 molecules and assessed the stability of each
peptide–HLA (pHLA) complex. We used HLA-B*44:05 molecule
as the refold yield was higher for this allomorph than for the HLA-
B*44:02/03. The NP338 peptide could bind each of the three HLA
molecules (HLA-B37, -B18, and -B*44:05); however, the stability
of HLA-B37-NP338 was superior by 6 °C to HLA-B18-NP338 and
by 14 °C to HLA-B*44:05-NP338 (Supplementary Table 1).
We then solved the binary structures of the NP338 peptide
presented by HLA-B37, HLA-B18, and HLA-B44 (Supplementary
Table 2, Fig. 1). The NP338 peptide adopted an extended
conformation in the cleft of HLA-B37, with the P2-Glu and P9-
Phe acting as anchor residues in the B- and F-pocket of HLA-B37,
respectively49. In addition to the primary anchor residues, the P5-
Arg acted as a secondary anchor residue, fully buried into the F-
pocket, and formed a salt bridge with Asp77 from the α1-helix in
the HLA-B37 molecule (Fig. 1a). The remaining six residues were
Table 1 HLA alleles predicted to bind the WT NP338–346
FEDLRVLSF peptide
Prediction score
range
HLA allele Prediction score HLA superfamily
>20 B*37 33 B44
B*44:02 25 B44
B*18 22 B44
15–20 B*08 17 B8
B*40:01 17 B44
B*45:01 17 B44
B*41:01 16 ND
B*14:02 15 B27
B*53:01 15 B7
B*38:01 15 B27
B*13 3 ND
A*68:01 2 A3
The http://www.syfpeithi.de/bin/MHCServer.dll/Info.htm prediction tool was used to assign a
prediction score that the WT NP338 peptide would be bound by the particular HLA allele.
Prediction scores were grouped into a predicted score range for clarity. ND refers to HLA alleles,
which have not been assigned a HLA superfamily. Alleles in bold were selected for further
analysis
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all solvent exposed and represented potential contacts for the
TCR. Comparison of the HLA-B37-NP338 with HLA-B18-NP338
and HLA-B44-NP338 complexes show an overall similar HLA-
binding cleft (Fig. 1d), with a root mean square deviation (r.m.s.
d.) of 0.2 and 0.4 Å, respectively. Similar to the HLA-B37-NP338
structure, the NP338 peptide was anchored to HLA-B18 and HLA-
B44 by P2-Glu and P9-Phe. However, the NP338 peptide adopted
a strikingly distinct conformation when bound to HLA-B37 as
compared with HLA-B18 (r.m.s.d. of the peptide 1.7 Å) and
HLA-B44 (r.m.s.d. of 1.8 Å for the peptide). In HLA-B18, P5-Arg
is partially buried in the D-/E-pocket and only exposed its
guanidinium group to the solvent, stabilized by a salt bridge with
the peptide P3-Asp (Fig. 1b). Polymorphism at position 116
between the two HLA molecules change the architecture of the
peptide. The HLA-B18 contains a small Ser116, while the HLA-
B37 has a large Phe116. As a result, P9-Phe of the peptide is
anchored deeper in the cleft in the HLA-B18 molecule, which
would sterically clash with the P5-Arg conformation observed in
HLA-B37. In addition, the salt bridge observed in HLA-B37
between Asp77 and P5-Arg would be lacking in HLA-B18 due to
the presence of Ser77. In HLA-B44, P5-Arg was fully exposed to
the solvent (Fig. 1c). Owing to the presence of four tyrosine
residues (9, 74, 99, 116) in the cleft of HLA-B44 located
underneath P5-Arg, Arg cannot be accommodated inside the cleft
and adopt a different conformation from the one observed in
HLA-B37, that only shares Tyr74. The additional anchor residue
observed in the B37-NP338 complex could explain the higher
stability of this pHLA complex (Supplementary Table 1). These
distinct conformations adopted by the NP338 peptide, due to HLA
polymorphism, changed the surface presented to the TCR. On
one hand, the NP338 peptide revealed a hydrophobic surface when
bound to HLA-B37, while on the other, it was an epitope with
central positively charged residues in the cleft of HLA-B18 and
HLA-B44.
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Fig. 1 NP338 elicits robust CD8+ T cell responses only in the context of HLA-B*37:01. a–d Crystal structures of a HLA-B*37:01 (purple), b HLA-B*18:01
(blue), and c HLA-B*44:05 (yellow) in complex with NP338 WT (represented in black stick). d is showing an overlay of the three peptide–HLA complexes in
cartoon representation, with NP338 colored accordingly to the bound HLA, namely, purple (HLA-B*37:01), blue (HLA-B*18:01), and yellow (HLA-B*44:05).
e–g PBMCs from HLA-B*37:01+ donors (n= 5), HLA-B*44:02+ donors (n= 5), HLA-B*44:03+ donors (n= 5), or HLA-B*18:01+ donors (n= 5) were
stimulated with a pool of NP338 peptides (10 μM each peptide, 30 μM total), and speciﬁcity was assessed in an ICS assay against 3 μM NP338 pool (1 μM
each peptide, HLA-B*44:02+ donors) directly into the well or 30 μM (10 μM each peptide, all other donors) NP338-pooled pulsed APC lines (HLA-B*37:01,
HLA-B*44:03, and HLA-B*18:01). CD8+ T cells are gated on lymphocytes, singlets, live+ (when stained with the second antibody cocktail only) CD3mid-high,
CD8+ T cells; as per Supplementary Fig. 2a. e Representative dot plots of IFNγ+TNFα+ production by pooled CD8+ T cell lines derived from HLA-B*37:01+,
HLA-B*44:02+, HLA-B*44:03+, or HLA-B*18:01+ donors, towards a pool of NP338 peptides. No peptide control represented in brackets. f Summary of IFNγ,
TNFα, and CD107a production, minus no peptide controls, against the pool of NP338 peptides (closed circle) or a positive control (ConA open square or PMA
closed square) across multiple donors. Statistical analysis using a Dunnett's two-way ANOVA in which *p≤ 0.05, **p≤ 0.01, and ***p≤ 0.001. g Summary
of the polyfunctional proﬁles, minus background, from the four HLA-B*37:01+ donors who responded towards the pool of NP338 peptides
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We next probed memory NP338+CD8+ T cell responses in
individuals expressing HLA-B*37:01, HLA-B*44:02, HLA-
B*44:03, or HLA-B*18:01 (Fig. 1e–g, Supplementary Table 3) by
stimulating their peripheral blood mononuclear cells (PBMCs)
with a pool of NP338 peptides corresponding to the main variants
in the circulating inﬂuenza A strains (Table 2). Following
10–16 days of peptide stimulation, we detected robust CD8+ T
cell responses by interferon-γ (IFNγ) and tumor necrosis factor-α
(TNFα) production as well as CD107a expression in the majority
(4/5) of HLA-B37+ donors (Fig. 1f, g), with a high level of
polyfunctionality (Fig. 1g). However, NP338+ CD8+ T cell
responses were undetectable in all (5/5) HLA-B*44:02, HLA-
B*44:03, or HLA-B*18:01 individuals (Fig. 1f, g), despite their CD8
+ T cells having responded strongly to non-speciﬁc stimulation by
phorbol 12-myristate 13-acetate or Concanavalin A (Fig. 1f).
Overall, these data suggest that HLA-B37, but not HLA-B44 or
HLA-B18, represents the HLA restriction for the NP338 peptide.
The lack of NP338+CD8+ T cell responses in the context of HLA-
B44 and HLA-B18 might be due to the distinct conformations, or
lower stability, of NP338 as compared to HLA-B37.
Cross-reactive NP338+CD8+ T cells towards NP338 variants.
Having shown robust NP338+CD8+ T cell responses in HLA-B37
donors, we next determined the level of cross-recognition towards
the main NP338 variants occurring in IAVs. Our conservation
analysis of the NP338 viral peptides across vaccine and circulating
IAV strains, including pH1N1, H5N1, and H7N9, found 16
natural variants of NP338 peptide (Table 2), with the most com-
mon mutations occurring at position (P) 5, 6, and 7 of the pep-
tide. Two major variants; FEDLRVSSF (NP338-L7S)
and FEDLRLLSF (NP338-V6L) were dominant in H1N1,
pH1N1, H5N1, and H7N9 or H3N2 strains, respectively, repre-
senting 93–100% of the distinct strains and were thus selected in
addition to the previously published (WT) peptide for further
analysis.
To assess the cross-reactive potential of HLA-B37-NP338+CD8+
T cells, pooled or variant-speciﬁc NP338 T cell lines were
generated using PBMCs from HLA-B37+ donors. We also
generated HLA-B37-NP338 and mutant HLA-B37-NP338-V6L
and HLA-B37-NP338-L7S tetramers. The ability to recognize, and
functionally respond, to each of the NP338 variant was then
assessed using tetramers and an intracellular cytokine staining
assay, respectively (Fig. 2). Staining with all three pHLA tetramers
and functional assays showed similar proportions of CD8+ T cell
staining/functional levels in all WT or variant-speciﬁc NP338-T
cell lines (Fig. 2a, c), suggesting that the majority of NP338-
speciﬁc CD8+ T cell lines were able to cross-recognize (Fig. 2a, c)
and respond to (Fig. 2b, c) each of the three distinct
peptides, indicating broad cross-reactivity towards these epitopes
(Fig. 2b, c). Interestingly, the NP338-V6L tetramer showed a
slightly stronger staining than the WT and NP338-L7S tetramers
(Fig. 2a).
CD8+ T cell lines typically recognized and responded most
prominently to the peptide they were generated against, with the
lowest level of cross-reactivity being observed by the NP338-V6L-
speciﬁc CD8+ T cell lines, when stimulated with the NP338-WT
(21.45 ± 18.86% by tetramer, 20.98 ± 19.80% by IFNγ, and
18.88±18.90% by TNFα) and NP338-L7S variant (16.31 ± 14.47%
by tetramer, 13.63 ± 12.04% by IFNγ, and 13.04 ± 11.65% by
TNFα). These data suggest that a high level of cross-reactivity
across different variants exists, although some variant-speciﬁc
reactivity can be also detected. These data highlight that such
cross-reactive CD8+ T cells may offer protection against H1N1,
H5N1, H7N9, and possibly other novel IAV strains.
To further assess whether the WT NP338 peptide elicited CD8+
T cell responses of high functional avidity, CD8+ T cell lines were
generated against the WT NP338 peptide (n= 3), and their
functional response was assessed towards decreasing concentra-
tions of the WT NP338 peptide (Fig. 2d). All data were normalized
to the maximal response (when stimulated with maximum
peptide). High and stable functional avidity towards NP338 (IFNγ,
TNFα, and CD107a) was observed in cell lines derived from all
three donors (Fig. 2d).
Our data show that HLA-B37+ individuals display polyfunc-
tional and highly cross-reactive CD8+ T cell response to the
NP338 epitope and its major variants.
Table 2 Conservation of NP338 epitope in distinct IAV strains
Sequence Abbreviation Frequency
IAV—H1N1 IAV—H3N2 Other IAV strains
All Aust Vacc All Aust Vacc pH1N1 All H5N1 All H7N9 All
FEDLRVLSF WT 0.9 2.4 1.9 6.3
FEDLRVSSF L7S 96.5 93.0 100.0 1.3 1.3 98.5 95.9 100.0
FEDLRLLSF V6L 0.8 95.6 96.9 93.8
FEDIRVSSF L4I+L7S 0.2 4.7
FEDLRVSSL L7S+F9L 0.1 2.3 0.1
FEDLRISSF V6I+L7S 0.5 0.7 3.1
FEDLRVSGF L7S+S8G 0.8 0.5 1.0
FEDLIVSSF R5I+L7S
FEDLKVLSF R5K 0.1
FEDLRVSSY L7S+F9Y 0.2 0.2
FEDLRVTSF L7T 0.1
FEDLGLLSF R5G+V6L 0.1
FEDLKLLSF R5K+V6L 0.3
FEDLRILSF V6I 0.1
FEDLRLLNF V6L+S8N 0.1
SEDLRLLSF F1S+V6L 0.1
Number of sequences 1155 43 9 1264 159 16 858 97 39
Coverage of selected
strains (%)
98.1 93.0 100.0 99.4 100.0 100.0 98.5 95.9 100.0
Sequences were obtained from the NCBI Inﬂuenza Research Database https://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nph-select.cgi?go=database. Full-length sequences of Australian
(denoted Aust), vaccine (denoted Vacc) and pH1N1, H5N1 and H7N9 were obtained and were aligned using the inﬂuenza database. Underlined are anchor residues for HLA-B*37:01, and mutations are
shown in bold. The ﬁrst three rows in italics represent sequences chosen for further analysis
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NP338 variants are molecular mimics of the WT NP338 epitope.
To understand the molecular basis of HLA-B37-NP338+CD8+ T
cell cross-reactivity, we solved the structures of two major NP338
variants, namely, NP338-V6L and NP338-L7S in complex with
HLA-B37 (Fig. 3; Supplementary Table 2). Both peptides bound
HLA-B37 in an extended conformation with the canonical P2-
Glu and P9-Phe49, while P5-Arg acted as a secondary anchor
residue (Fig. 3a, b). Superimposition of the HLA-B37-NP338
binding cleft with either HLA-B37-NP338-V6L (Fig. 2c) or HLA-
B37-NP338-L7S (Fig. 2d) revealed a similar conformation of the
HLA-binding cleft (r.m.s.d. of 0.08 Å). In addition, the peptides
adopted a similar conformation as the NP338 peptide with an r.m.
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s.d. of 0.12 and 0.09 Å, respectively (Fig. 3e, f). The hydrophobic
P6-Val residue sits near the α2-helix and interacts with Val152,
Gln155, and Asp156 of the HLA (Fig. 3g). The substitution of P6-
Val for P6-Leu in the H3N2 was readily accommodated in the
HLA-B37 cleft and did not change either the peptide or HLA
conformation (Fig. 3h). The P7-Leu residue sits above Trp147,
with its side chain interacting with Ala150, Val152, and Lys146
(Fig. 3i). The substitution from P7-Leu to P7-Ser did not impact
the conformation of either the peptide or HLA molecule (Fig. 3j).
We also showed that the two NP338 variants could stabilize HLA-
B37 as efﬁciently as the NP338 WT peptide (Supplementary
Table 1).
Overall, the two major variants of the NP338 epitope adopted
the same conformation as the NP338 epitope and represent
molecular mimics of the WT peptide, which might favor T cell
cross-reactivity.
Key TCRs cross-recognize NP338 variants directly ex vivo. To
investigate HLA-B37-NP338+CD8+ T cell cross-reactivity at a
molecular level, PBMCs from healthy HLA-B37+ donors (n= 3)
were stained with WT and variant HLA-B37-NP338 tetramers
individually, magnetically enriched, and single-cell sorted. TCRαβ
repertoire was determined using a multiplex RT-PCR37. As
expected, prominent CD8+ T cell memory pools could be
detected directly ex vivo using NP338, NP338-V6L, and NP338-L7S
tetramers (Fig. 4a), with magnetic enrichment increasing the
proportion of NP338-speciﬁc CD8+ T cells >100-fold. CD8+
T cells directed at the HLA-B37-NP338 epitopes in healthy donors
were of the memory phenotypes characterized by CD27hi and
CD45RAlow-med expression (Fig. 4a). Interestingly, NP338-V6L-
speciﬁc CD8+ T cells were found at the highest average fre-
quency, at 1 in every 5.97 × 10−4 CD8+ T cells, followed by NP338
and then NP338-L7S-speciﬁc CD8+ T cells found at frequencies of
1 in 2.31 × 10−4 and 1.86 × 10−4 CD8+ T cells, respectively
(Fig. 4b).
The TCRαβ repertoire across all three donors (Fig. 5,
Supplementary Table 4) was entirely private, meaning no shared
TCRαβs were detected between the donors, and of comparable
diversity, comprising 13.67 ± 5.77, 11.67 ± 0.58, and 10.33 ± 2.08
distinct TCRαβ clonotypes (Donors 1–3, respectively). A TRBV19
bias was detected in all donors (19.01 ± 18.54%, 39.88 ± 27.32%,
and 37.36 ± 33.49% in Donors 1–3, respectively), while Donor 1
displayed an additional TRBV27 bias (26.01 ± 16.12%; Fig. 5,
Supplementary Table 4). Interestingly, only one or two high-
frequency but unique clonotypes were able to cross-recognize all
three NP338 variants, and 69.24 ± 16.65%, 44.25 ± 34.87%, and
53.45 ± 5.76% cross-reactivity was observed in Donors 1–3,
respectively. Interestingly, each of these donors utilized different
pairings to achieve universal cross-reactivity. Donor 1 favored
TRAV14/TRBV20-1 and TRAV29/TRBV27, Donor 2 TRAV35/
TRBV19, and Donor 3 TRAV23/TRBV27 and TRAV21/TRBV9
pairings (Supplementary Table 4). In addition, TRBV19+ cross-
reactive TCR clonotypes were detected in all donors.
With respect to the CDR3α/β length, 9-mer CDR3α and 9-10-
mer CDR3β loops were preferentially used for the recognition of
NP338 (Fig. 5b, c). Together, these data highlight the potential of
common HLA-B37-NP338+CD8+ TCRαβ clonotypes to provide
protection against distinct IAV strains.
The frequency of cross-reactivity was increased (81.35 ±
19.72%) following in vitro expansion with the WT NP338 peptide
(Supplementary Fig. 1). Donor 3’s TCRαβ repertoire was more
restricted following in vitro ampliﬁcation comprising fewer
distinct clonotypes (7.33 ± 2.08) and displayed a stronger
TRBV19 bias (Supplementary Fig. 1ab). Again, 7–10-mer CDR3α
and 8–9-mer CDR3β lengths were preferred in the recognition of
NP338 (Supplementary Fig. 1c). A single TCRαβ clonotype
(termed EM2: TRAV30/TRBV19, CDR3α: CGTERSGGYQKVTF,
and CDR3β: CASSMSAMGTEAFF) was able to cross-react with
all three NP338 peptides, therefore providing universal HLA-B37-
NP338+CD8+ recognition.
Overall, despite entirely private TCRαβ repertoires being
detected within each individual, a high level of inter-variant
cross-reactivity was achieved in each donor, facilitated by key
TCRs.
Biased TRBV19+ TCR chains mainly contacts the HLA-B37.
To further understand the molecular mechanism underlying T
cell cross-reactivity, we then investigated the cross-reactive clo-
notype described above (EM2 TCR; TRAV30/TRBV19, Supple-
mentary Table 4) that was able to recognize NP338 and its two
most common variants. We solved the structure of the EM2 TCR
in complex with HLA-B37-NP338 (Supplementary Table 2,
Fig. 6). The EM2 TCR docked centrally onto HLA-B37-NP338
with a 66° angle (Fig. 6b), falling in the range previously observed
for TCR-pHLA-I (average of 63°)50. The buried surface area
(BSA) of the complex was of ~1800 Å2, also falling in the pre-
viously observed range for TCR-pHLA-I (average of 1900 Å2)50.
The EM2 TCR α-chain contributes to 40% of the contact surface
(Fig. 6c), while the biased TRBV19+ β-chain contributes to 60%
of the BSA, providing a direct basis for the TRBV19 bias observed
in HLA-B37+ donors in response to NP338 and its variants. The
peptide contributed to 25% of the pHLA BSA, with all six solvent-
exposed residues contacted by the EM2 TCR. CDR2β (27%),
CDR3α (23%), and CDR3β (20%) are the highest contributors to
the BSA, followed by CDR1α, CDR2α, and CDR1β (6–8% each),
as well as the framework (FW) residues of the β-chain (9%)
(Fig. 6c).
All of the CDR loops of the EM2 TCR contacted the HLA-B37
molecule (Fig. 6d), with the addition of two FW residues from the
β-chain (Gln67β and Lys83β). From the EM2 α-chain, the CDR1/
2 loops contributed to ~10% of the TCR-HLA BSA and 16% for
the CDR3α (Supplementary Table 5). The CDR1/2α loops made a
contact with the region before the hinge of the HLA α2-helix
(residue 151–158, Fig. 6f), while the CDR3α loop contacted the
N-terminal part of the HLA α1-helix (residues 58 and 62, Fig. 6g).
Within the β-chain, the CDR1 made only few contacts with the
HLA (~2% TCR-HLA BSA), and the contacts were driven by
CDR2β (34%), CDR3β (14%), as well as FWβ (11%) (Fig. 6d).
The CDR3β loop contact with the HLA focused mostly on
Gln155, which has its side chain sandwiched by the Tyr30α
(CDR1α) and the 110SAMGT114 motif from the CDR3β loop
(Supplementary Table 5, Fig. 6h). The FW residue Lys83β formed
Fig. 2 NP338-speciﬁc CD8+ T cell lines cross-react with variant NP338 peptides. PBMCs from HLA-B*37:01+ donors (n= 4) were stimulated with a pool
(10 μM each, 30 μM total) or individual (10 μM) NP338 peptides for 10–11 days and cross-reactivity was assessed by tetramer staining and ICS assays.
Gating strategy: lymphocytes, singlets, live+, CD3mid-high, CD8+ T cells; as per Supplementary Figure 2a, b. a Representative dot plots of a pooled NP338-
speciﬁc CD8+ T cell line stained with each NP338 variant tetramers. b Representative dot plots of IFNγ+TNFα+ production by pooled NP338-speciﬁc CD8+
T cells. c Summary of tetramer staining, IFNγ (minus no peptide control), and TNFα (minus no peptide control) production by pooled or variant-speciﬁc
NP338-speciﬁc CD8+ T cell lines in Donors 1–3. d Summary of IFNγ, TNFα, and CD107a production, minus no peptide control, of WT-speciﬁc CD8+ T cell
lines from Donors 1, 2, and 4 in response to concentrations ranging between 10 μM and 0.125 μM of the WT-NP338 peptide. Values are represented as a
proportion of maximum tetramer staining or cytokine production against the line-speciﬁc peptide
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a network of salt bridge with the HLA-B37 Glu76 and CDR1β
Asp30, hovering above P8-Ser (Fig. 6i). The CDR2β loop form a
hairpin loop that sat above the HLA α1-helix covering a large
stretch of the HLA helix spanning from residue 65 to 79 (Fig. 6b,
d, j and Supplementary Table 5). The residue Gln67β from the
FW, located downstream of the CDR2β loop was also contacting
the α1-helix of the HLA-B37 molecule. Gln57β, Asn60β, Asp61β,
and Gln67β were forming a large hydrogen network with the
HLA-B37 molecule.
Overall, CDR2β and FWβ make extensive interaction with the
HLA-B37 molecule, providing a basis for the strong bias TRBV19+
usage observed in the donors.
EM2 TCR contacts the NP338 peptide via a hydrophobic net-
work. The peptide is predominantly contacted by CDR3α (47%)
and CDR3β (26%), as well as by CDR1β (17%) and CDR2β (10%)
(Fig. 6b, e, Supplementary Table 5). The motif SGG within the
CDR3α loop, with small or no side chain, allow the loop to be in
close proximity and lodge itself between the side chains of P1-Phe
and P3-Asp (Fig. 7a). The proximity of the loop allows the
Gln113α to form hydrogen bonds with P3-Asp of the peptide and
hydrophobic interaction with P4-Leu. Therefore, CDR3α loop
forms a lid-like structure that covers the N-terminal part of the
peptide (Supplementary Table 5). Within the EM2 TCR β-chain,
all the CDR loops were contacting the peptide C-terminal section
from residue P4-Leu to P8-Ser. P4-Leu was contacted by Gln57β
from the CDR2β loop, while the CDR1β loop was interacting with
both P7-Leu and P8-Ser that form a hydrogen bond with Asp30β
(Supplementary Table 5). P6-Val and P7-Leu were both contacted
by the CDR3β loop that sat on top of the central region of the
peptide and form Van der Waals interaction. The 109MSAM112
motif from the CDR3β loop could hover on the central part of the
peptide due to the small side chains of the 110SA111 residues. The
CDR3β loop was thus making contacts with P6–P7 residues of the
peptide mainly via Van der Waals bonds (Supplementary Table 5).
Interestingly, the comparison of HLA-B37-NP338 in its free and
liganded state with the EM2 TCR revealed that the peptide (r.m.s.
d. of 0.2 Å) and HLA-B37 (r.m.s.d. of 0.3 Å) did not change
conformation upon TCR binding (Fig. 7c). The hydrophobic
nature of the interaction between the EM2 TCR and the NP338
peptide is complementary with the conformation of the NP338
peptide bound to HLA-B37 that presents only the hydrophobic
residue to the TCR. This might explain the lack of response for
NP338 when presented by both HLA-B18 and HLA-B44
molecules, in which the peptide presents its charged P5-Arg to
the TCR (Fig. 1b, c).
Altogether, the structure of the EM2 TCR–HLA-B37-NP338
complex revealed that the TCR is using hydrophobic interaction
from its CDR3 loops to engage with the all stretch of the NP338
peptide.
EM2 TCR afﬁnity for NP388-V6L is higher than for NP388-WT.
We next evaluated the ability of the EM2 TCR to recognize the
NP338 and its two major variants (NP338-V6L and NP338-L7S)
NP338-V6L
f i j
a c d
e g h
b
NP338-L7S
NP338-V6LNP338-WT
NP338-WT
NP338-L7S
Asp77
Asp77
Asp77
Asp77
P5-R
P5-R
P5-R
P5-R
P7-L
P6-L
P7-SP6-V
P6-L/V
P6-V
P7-L
P7-L/S
P7-L P7-S
P6-V P6-L
Gln155 Gln155Val152Val152
Asp156 Asp156
Lys146 Lys146
Ala150Ala150
Trp147 Trp147Val152 Val152
P6-L/V
P7-L/S
Fig. 3 Structures of HLA-B37 bound to NP338 and its two variants. Structure of the HLA-B37 (white cartoon) presenting either a NP338-V6L (orange) or b
NP338-L7S (green). c, d Top view or e, f side view of the structural overlay of HLA-B37 (white cartoon) presenting the NP338 (purple) with either c, e NP338-
V6L (orange) or d, e NP338-L7S (green). g–j Zoomed in view on the HLA-B37 interaction with residue at position 6 (g, h) and position 7 (i, j) of the NP338
(purple), NP338-V6L (orange) and NP338-L7S (green) peptides. The red dashed lines represent salt bridges between residues
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using surface plasmon resonance (Fig. 7d–f; Supplementary
Table 6). The EM2 TCR bound to the HLA-B37-NP338 complex
with a Kd of ~130 µM (Fig. 7d), displaying a low afﬁnity for an
antiviral CD8+ T cell, the average being 35 µM50. The EM2 TCR
bound to NP338-L7S with a similar afﬁnity to the one observed for
the NP338 bound to HLA-B37 (Kd ~ 150 µM, Fig. 7e). Interest-
ingly, the EM2 TCR afﬁnity was increased by four-fold for the
NP338-V6L (Kd ~ 30 µM, Fig. 7f) compared to NP338 when bound
to HLA-B37.
The structures of each NP338 and variants in complex with the
HLA-B37 molecule (Fig. 3, Supplementary Table 2) allowed us to
understand the impact of the NP338 mutation onto the EM2 TCR
recognition. Overlay of the HLA-B37-NP338-L7S with the EM2
TCR-HLA-B37-NP338 structures showed that the smaller P7-Ser
would be readily accommodated by the EM2 TCR without
structural changes (Fig. 7g). This might explain the similar
afﬁnity observed for the EM2 TCR towards both peptides (Kd ~
130–150 µM). In a similar fashion, an overlay of the HLA-B37-
NP338-V6L with the EM2 TCR-HLA-B37-NP338 structures
(Fig. 7h) shows that the larger side chain of the P7-Leu might
create additional contact with the CDR3β loop and might in turn
provide a basis for the improved afﬁnity observed for the EM2
TCR towards the HLA-B37-NP338-V6L (Kd ~ 30 µM).
Thus our data demonstrate that CD8+ T cell cross-reactivity in
the context of NP338 peptide and its variants is favored by similar
conformations adopted by the epitopes.
Key TCRs are cross-reactive towards A1-NP44 variants. To
investigate whether cross-reactivity and thus protection against
distinct IAV strains is NP338-speciﬁc or occurs towards other
IAV-speciﬁc epitopes, we assessed CD8+ T cell responses towards
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the HLA-A1-restricted NP44 peptide (Fig. 8). Conservation ana-
lysis revealed that there were two major variants of the peptide,
the CTELKLSDY (NP44) and the S7N mutant CTELKLNDY
(NP44-S7N), covering 34–100% of H3N2, H7N9, H5N1, and
H1N1 virus strains (Supplementary Table 7). To investigate
cross-reactivity towards these variant NP44 peptides, PBMCs
from healthy HLA-A1+ donors (n= 3) were tetramer stained
with each of the NP44 variants directly ex vivo and magnetically
enriched and single-cell sorted (Fig. 8a). The TCRαβ repertoire
was then determined using multiplex RT-PCR (Fig. 8b). Two of
the three donors (Donors 1 and 20) had both NP44- and NP44-
S7N-speciﬁc CD8+ T cell populations. Interestingly, Donor 21
had only a NP44-speciﬁc CD8+ T cell population, with no
detectable S7N-speciﬁc CD8+ T cell population (Fig. 8b). A
predominant TRAV8-2+ TCRα chain expressing a CDR3α
sequence CVVSDRNFNKFYF paired with multiple distinct
TCRβs and was detected in two out of three donors (Supple-
mentary Table 8). Similar to the NP338 system, speciﬁc clonotypes
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isolated from Donor 1 could recognize both NP44 variants, while
the remainder of the repertoire was variant speciﬁc (Fig. 8b).
Interestingly, the TCRαβ repertoire of Donor 20 was entirely
NP44 variant speciﬁc. We previously solved the structures of both
NP44 and NP44-S7N peptides in complex with the HLA-A1
molecule23. In similar fashion as HLA-B37 and the NP338 var-
iants, the NP44 variants adopted similar conformation in the cleft
of HLA-A1 molecule. This suggests that here too molecular
similarity might underpin CD8+ T cell cross-reactivity and favor
the recognition of multiple IAV strains.
Overall, these data show that TCRαβ cross-reactivity is not limited
to the recognition of HLA-B37-NP338 and highlight the importance
of cross-reactive CD8+ T cells in the recognition of virus-infected
cells and thus their potential to protect against distinct IAV strains.
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Discussion
There is great interest in the development of a universal CD8+ T
cell-mediated vaccine towards IAV. However, to realize this, ﬁrst a
thorough understanding of prominent human inﬂuenza-speciﬁc
CD8+ T cell epitopes is needed. We have previously shown that NP
is the most immunogenic antigen in both HLA-A*02:01-positive51
and -negative individuals39. However, as the conservation of the
known inﬂuenza epitopes varies between 16% and 56%, depending
on ethnicity23, understanding inter-epitope cross-recognition across
diverse IAV strains is needed. In this study, we have used the
variable NP338 and NP44 peptides to dissect CD8+ T cell recogni-
tion of different peptide variants and thus distinct IAV strains.
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NP338 has two major variant peptides, covering ~93% (NP338-
L7S) and ~96% (NP338-V6L) of H1N1 and H3N2 viruses,
respectively. Although CD8+ T cell responses are highly peptide
speciﬁc34, they can tolerate variations within CD8+ T cell
peptides22,29,30,34. We identiﬁed functional cross-reactivity
towards the variant NP338 peptides, albeit to different levels.
Using a multiplex RT-PCR for the detection of the TCRαβ
repertoire directly ex vivo, we conﬁrmed that CD8+ T cells were
cross-reactive towards these distinct NP338 variants, at a clono-
typic level, with ∼55% TCRαβ repertoire being capable of
recognizing multiple NP338 variants. Interestingly, unique clo-
notypes with distinct TRAV–TRBV pairings in each individual
recognized all three NP338 variants. Furthermore, this cross-
reactivity was increased following in vitro ampliﬁcation, poten-
tially suggesting that activation increases expansion of cross-
reactive clones, allowing certain TCRαβ clonotypes to recognize
distinct viral variants and potentially prevent viral escape.
Additionally, we showed that the importance of cross-reactive
TCRαβ repertoires is not limited to the recognition of NP338 and
that cross-reactive CD8+ TCRαβ can recognize HLA-A1-
restricted NP44 variant peptides.
To understand the molecular basis of cross-reactive TCRαβ
recognition, we solved the structure of NP338 and its variants
bound to the HLA-B37 molecule, as well as the structure of a
cross-reactive TCR in complex with HLA-B37-NP338. First, our
data show that the two NP338 variants were structural mimics of
the WT peptide. Second, the NP338 peptide conformation was not
altered by TCR engagement, and therefore the conserved struc-
ture of the NP338 variants favored TCR cross-reactivity, a
mechanism that is thought to underpin cross-reactivity and
alloreactivity more broadly45,52,53. The structures also demon-
strated that only HLA-B37, and not HLA-B18 nor HLA-B44,
binds the NP338 with a secondary anchor residue (P5-Arg),
revealing the hydrophobic surface of the NP338 peptide, which
might help cross-reactivity36,54. This hydrophobic surface of the
NP338 was disrupted when the peptide was presented by HLA-
B44 or HLA-B18 molecules, which exposed the charged P5-Arg,
and for which no T cell recognition was observed.
Together, these data imply that HLA-B37+ donors may have a
level of protection against H1N1, pH1N1, H3N2, H5N1, H7N9,
and possibly novel IAV strains. Furthermore, the ﬁndings high-
light the potential of inducing inter-strain cross-protection by the
inclusion of a single peptide variant in a CD8+ T cell-mediated
vaccine, suggesting that vaccine epitope identiﬁcation will no
longer need to focus solely on conserved epitopes for universal
inter-strain cross-protection.
Diverse and cross-reactive TCR repertoires are important for
viral control and preventing viral escape27,29, and we thus dis-
sected the importance of TCRαβ diversity in the recognition of
the variant NP338 peptides. Our data show that cross-recognition
of distinct IAV strains is underpinned by a diverse TCR reper-
toire and surprisingly that no shared clonotypes could be detected
between individuals. This highlights that cross-reactivity and
TCRαβ repertoire diversity may provide further protection
against distinct IAV strains. Furthermore, TCRαβ diversity is
likely to aid in limiting viral escape, offering protection against
any quasispecies that arise during infection. Additionally, we have
shown that cross-reactivity towards distinct IAV strains is not
limited to HLA-B37-NP338, and cross-reactive TCRs towards the
HLA-A1-restricted NP44 were also observed. In both contexts, we
have isolated cross-reactive clonotypes that were not shared
between individuals, showing the plasticity of the TCR repertoire
whereby multiple TCRs are able to cross-react and provide pro-
tection against multiple IAV strains.
Overall, our study provides evidence that inter-epitope cross-
reactivity is common for the human inﬂuenza epitopes and
occurs for prominent HLA-B37-restricted NP338 and HLA-A1-
restricted NP44 epitopes, in addition to previously published
HLA-A*02:01-restricted M15830. CD8+ T cells can recognize
variations within CD8+ T cell epitopes and cross-reactive CD8+
TCRαβ repertoires can recognize variant HLA-B37-restricted
NP338 and HLA-A1-restricted NP44 peptides across donors.
Together, these data highlight the importance of CD8+ T cell
cross-reactivity and diversity in the protection against distinct
IAV strains and the induction of such diverse and cross-reactive
CD8+ T cells by a CD8+ T cell-mediated vaccine could provide
universal and superior protection against distinct IAV strains.
Methods
Ethics statement. All work was undertaken in line with the Australian National
Health and Medical Research Council (NHMRC) Code of Practice, with ethics
approval by the University of Melbourne Human Ethics Committee, ethics num-
bers 0931311 and 1443389. Australian Red Cross Blood donors provided written
informed consent on the day of their blood donation. Written informed consent
was obtained from all healthy blood donors. Donor information including HLA
typing result is reported in Supplementary Table 3.
NP338 conservation analysis. Full-length vaccine, Australian, pH1N1, H5N1, and
H7N9 isolates with identical sequences collapsed were obtained from the NCBI
Inﬂuenza Research Database https://www.ncbi.nlm.nih.gov/genomes/FLU/
Database/nph-select.cgi?go=database in February 2018. Sequences were aligned
using https://www.ﬂudb.org/brc/home.spg?decorator=inﬂuenza.
Antigen-presenting cell lines (APC lines). APC lines were kindly provided by
Professor James McCluskey (University of Melbourne, VIC, Australia; C1R-
B*44:03) and Dr. Nicole Mifsud (Monash University, VIC, Australia; C1R-
B*18:01). The A2-20091204 (HLA-B*37:01+) BLCL cells were provided by Pro-
fessor Weisan Chen (LaTrobe University, VIC, Australia).
Isolation of PBMCs. Buffy coats were obtained from the Australian Red Cross
Blood Service (ARCBS) and whole blood donations from healthy volunteers.
PBMCs were separated using density gradient separation and were cryopreserved
until use. All samples were HLA-typed by the Victorian Transplant and Immu-
nogenetics Service (VTIS, West Melbourne, VIC, Australia) at the ARCBS tissue-
typing Laboratory.
Generation of NP338-speciﬁc CD8+ T cell lines. PBMCs were used to generate
CD8+ T cell lines at a 1:2 stimulator-to-responder ratio. Stimulator PBMCs were
washed in fetal calf serum (FCS)-free media and were pulsed with 10 μM (unless
otherwise stated) peptide for 90 min at 37 °C with 5% CO2. Stimulator PBMCs
were washed twice and added to the responder PBMCs. Cells were cultured for
10–16 days and supplemented twice weekly with 10 U/mL rIL-2 (Roche, Basel,
Switzerland) from day 4.
Intracellular cytokine staining. APC lines expressing HLA-B*37:01, HLA-B*18:01
or HLA-B*44:03 were pulsed with 10 μM peptide (unless otherwise stated) in FCS-
free media for 1 h at 37 °C with 5% CO2. APCs were subsequently washed twice
and added to CD8+ T cell lines at 1:2 APC-to-T cell ratio. Alternatively, CD8+ T
cell lines from HLA-B*44:02+ donors were stimulated directly with 1 μM peptide
without APCs. Cells were co-cultured for 5–6 h in the presence of 10 U/mL IL-2, 5
μMMonensin A (Sigma Aldrich, MO, USA) and Golgi-Stop (BD eBiosciences, CA,
USA) with aCD107a-FITC/AF488 (1:100–1:200; eBiosciences # 53-1079-41, CA,
USA) for 5 h. Following activation, cells were surface stained for 30 min with
αCD3-PE (1:25–1:50; BD Pharmingen # 555333, CA, USA), αCD8-APC
(1:50–1:100; BD Biosciences # 340584, CA, USA) with or without Live/Dead-NIR
(1:1000; Molecular Probes Cat#L10119, MA, USA), or αCD3-Pey7 (1:50–1:100;
eBiosciences # 25-0038-42), αCD8-PerCPCy5.5 (1:50; BD Biosciences # 341051)
and Live/Dead-NIR (1:1000; Molecular Probes #L10119). Cells were then ﬁxed
with 1% paraformaldehyde (PFA; Electron Microscopy Sciences, PA, USA) or BD-
Fix-Perm buffer (BD Biosciences) for 15–20 min. Cells were intracellularly stained
for 30 min or overnight with anti-IFNγ-PerCPCy5.5 (1:100; eBiosciences #45-7319-
41) and anti-TNFα-PeCy7 (1:100; BD Pharmingen #557647, CA, USA), anti-IFNγ-
PE (1:40; BD Biosciences #340452) and anti-TNFα-APC (1:50–1:100; BD Bios-
ciences #340534) or anti-IFNγ-V500 (1:50–1:100; BD Horizon #561980, NY, USA)
and anti-TNFα-APC (1:50–1:100; BD Biosciences #340534) in perm wash buffer
(BD Biosciences), or 0.3% Saponin (Sigma, MO, USA), respectively. Cells were
washed, acquired on the BD FACS Canto II (BD Biosciences) and analyzed using
the Flowjo software version 9.7.6 (Treestar, OR, USA).
Tetramer staining of CD8+ T cell lines. CD8+ T cells were stained with tetra-
mers for 1 h at room temperature in the dark. Cells were washed and surface
stained for 30 min with αCD3-PeCy7 (1:50–1:100; eBiosciences #25-0038-42) or
αCD3-PB (1:50–1:100; Biolegend #300431, SD, USA) with αCD8-PerCPCy5.5
(1:50; BD Biosciences #341051), αCD27-APC (1:50–1:100; BD Biosciences
#337169), αCD45RA-FITC (1:50–1:100; BD Pharmingen #555488) and Live/Dead-
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NIR (1:1000; Molecular Probes #L10119) at 4 °C, then either ﬁxed with 1% PFA
(Electron Microscopy Sciences), and acquired on the BD FACS Canto II (BD
Biosciences) or resuspended in sort buffer and single-cell sorted on the BD Aria III
(BD Biosciences).
Ex vivo magnetic enrichment of PBMCs. In all, 1–2 × 107 PBMCs from HLA-
B*37:01+ donors were FcR blocked in MACS buffer (phosphate-buffered saline
(PBS), 0.5% bovine serum albumin (BSA); Gibco, CA, USA, 0.2 nM EDTA; Ajax
Finechem, NSW, Australia) for 15 min at 4 °C (Miltenyi Biotech, Bergisch Glad-
bach, Germany) and tetramer stained with variant-speciﬁc tetramers conjugated to
PE in MACS buffer for 1 h at room temperature. Cells were washed, a small
amount was removed for unenriched control, and labeled with anti-PE microbeads
(Miltenyi Biotech, Bergisch Gladbach, Germany) for 30 min at 4 °C. Following
washing, cells were enriched by passing twice over LS magnetic columns (Miltenyi
Biotech, Bergisch Gladbach, Germany)30,55. Bound cells were eluted in MACS
buffer. All samples (unenriched, enriched, and ﬂow-through) were surface stained
for 30 min with αCD3-PeCy7 (eBiosciences), αCD8-PerCPCy5.5 (BD Biosciences),
Live/Dead-NIR (Molecular Probes), αCD14-APCH7 (BD Pharmingen), αCD4-
APCH7 (BD Biosciences), αCD19-APCH7 (Biolegend), αCD27-APC (BD Bios-
ciences) and αCD45RA-FITC (BD Pharmingen) at 4 °C in the dark. Lymphocytes
were washed, re-suspended in sort buffer (PBS, 0.1% BSA; Gibco, CA, USA), and
were acquired on the BD Aria III.
Single-cell multiplex RT-PCR for TCRαβ analysis. Epitope-speciﬁc CD8+ T cells
from PBMCs or CD8+ T cell lines were tetramer and antibody stained, as described
above. Following surface staining, cells were re-suspended in sort buffer (PBS
+0.1% BSA). Single epitope-speciﬁc CD8+ T cells were sorted on the BD FACS
Aria III (BD Biosciences) directly into PCR plates (Eppendorf, Hamburg, Ger-
many). cDNA was synthesized using the VILO RT Kit at 1/20 of the manufacturer's
recommendation, supplemented with 0.1% Triton X (Sigma, MO, USA)30,37,56.
The resulting cDNA was subject to a nested PCR containing 40-Vα and 27-Vβ
primers and Cα and Cβ primers (Supplementary Table 9). PCR products were
puriﬁed using Exo-Sap or Exo-Star (GE Healthcare, Buckinghamshire, UK) and
were sequenced using BigDyeV3.1 (Applied Biosystems, CA, USA). Sequencing
products were cleaned using DyeEx sequencing plates (Qiagen, Limburg, Nether-
lands) and sequencing was performed by the Department of Pathology at the
University of Melbourne (Melbourne, VIC, Australia). Sequences were analyzed
using Finch TV (Geospiza, WA, USA) and the IMGT query software57,58 (www.
imgt.org/IMGT_vquest). CDR3 amino acid sequences described within the text are
productive (no stop codons and an in-frame junction) TCRαβ pairs and start from
CDR3-position 1, as determined by the IMGT query software. CDR3 length is
calculated from position 4 and excludes the ﬁnal xF motifs. TRAV and TRBV
nomenclature was derived from IMGT www.imgt.org/IMGTrepertoire/
LocusGenes/#J.
NP338+CD8+ T cells with two alpha or beta chains were dissected by
performing the internal round of PCR with the speciﬁc individual primers and
subsequently sequenced using the relevant constant reverse primer or variable-
speciﬁc primers (Supplementary Table 9). Where possible, both chains were
resolved; however, in a few instances only the dominant chain could be resolved.
TRBV19+ TCRβs were sequenced with the TRBV19 forward primer (and are thus
referred to as TRBV19) and CDR3 regions were determined using the EXPASY
translate tool.
In cases when NP338+CD8+ TCRα or TCRβ chains could not be resolved,
sequences (two cells per clonotype) were resolved by cloning and colony PCR. PCR
products were ligated into a pGEM-T Easy Vector (Promega, WI, USA) overnight
at 16 °C. DH5α cells were then transformed with this vector and were grown,
plated on Luria agar plates (containing 100 μg/mL ampicillin, Media Preparation
Unit, Department of Microbiology and Immunology, University of Melbourne,
VIC, Australia) for 16–18 h, and were selected using X-gal (800 μg). Individual
transformed colonies were ampliﬁed by PCR with 20 pmol sense and anti-sense
vector primers (Supplementary Table 9). PCR were ampliﬁed as follows: 1 cycle of
95 °C for 5 min, 30 cycles of 95 °C for 30 s, 57 °C for 30 s, and 72 °C for 1 min,
followed by 1 cycle of 95 °C for 1 min, 57 °C for 1 min, and 72 °C for 7 min.
Products were visualized on a 2% agarose gel and were sequenced as above with 5
pmol of sense vector primer (Supplementary Table 9).
Protein expression, puriﬁcation, and crystallization. The EM2 TCR contained
an engineered disulﬁde linkage in the constant domains between the TRAC and
TRBC. The α- and β-chains were expressed separately as inclusion bodies in a BL21
Escherichia coli strain. The inclusion bodies were washed and suspended in 6M
guanidine, then mixed into a cold refolding solution containing 5M urea, 100 mM
Tris-HCL (pH 8), 2 mM EDTA, 400 mM L-arginine-HCl, 0.5 mM oxidized glu-
tathione, and 5 mM reduced glutathione. The refolding solution was dialyzed after
3 days against 10 mM Tris-HCl (pH 8) and 150 mM NaCl and then puriﬁed using
anion exchange and size exclusion columns59. All peptides were purchased from
Genescript (NJ, USA). HLA-B*37:01+-restricted peptides include WT-NP338-346
(FEDLRVLSF), L7S-NP338-346 (FEDLRVSSF), and V6L-NP338-346 (FEDLRLLSF).
Soluble class I heterodimers (with or without BirA tag at the C-terminal) of HLA-
B*18:01 and HLA-B*44:05 containing the NP338 peptides and HLA-B*37:01
containing the NP338 and variant NP338-L7S and NP338-V6L peptides were pre-
pared similarly to the TCR without urea in the refolding solution59. Crystals of the
EM2 TCR–HLA-B*37:01-NP338 complex or the pHLA individually in 10 mM Tris-
HCl (pH 8.0) and 150 mM NaCl were grown by the hanging-drop, vapor-diffusion
method at 20 °C with a protein to reservoir drop ratio of 1:1 and a protein con-
centration of 6–10 mg/mL. The pHLA crystals formed in 20% PEG 6000, 0.2 M
NaCl, 0.1 M Na citrate pH 6.5 while the EM2 TCR-HLA-B*37:01-NP338 complex
crystals formed in 19% PEG 3350 and 0.2 M di-ammonium tartrate. Monomers of
pHLA with the BirA tag construct were biotinylated and tetramerized in a 1:4 ratio
with PE-streptavidin (Life Technologies, CA, USA) in 6 additions over the course
of 1 h.
Data collection and structure determination. Crystals were soaked in a cryo-
protectant solution containing mother liquor solution with the PEG concentration
increased to 30% (weight per volume) and then ﬂash frozen in liquid nitrogen.
Data were collected on the MX1 beamline at the Australian Synchrotron, Clayton
using the ADSC-Quantum 210 CCD detector (at 100 K)60. Data were processed
using the XDS software61 and scaled using the XSCALE software61. The pHLA and
EM2 TCR-HLA-B*37:01-NP338 complex structures were determined by molecular
replacement using the PHASER62 program with the HLA-A*02:01-NLV complex
as the search model for the HLA without the peptide (Protein Data Bank accession
number, 3GSO59) and the LC13 TCR for the TCR (Protein Data Bank accession
number, 1KGC63). Manual model building was conducted using the Coot soft-
ware64 followed by maximum-likelihood reﬁnement with PHENIX65 and Buster
programs66. The TCR was numbered using the IMGT nomenclature57. The ﬁnal
models have been validated using the Protein Data Base validation website and the
ﬁnal reﬁnement statistics are summarized in Supplementary table 2. Coordinates
were validated by the PDB database. All molecular graphic representations were
created using PyMol67.
Thermal stability assay. The thermal stability assay was performed in the Real
Time Detection system (Corbett RotorGene 3000) using the ﬂuorescent dye Sypro
orange to monitor protein unfolding. The pHLA complexes (5 and 10 μM) in 10
mM Tris-HCl pH 8 and 150 mM NaCl were heated from 30 to 95 °C with a heating
rate of 1 °C/min. The ﬂuorescence intensity was measured with excitation at 530
nm and emission at 555 nm. The thermal melt point (Tm) represents the tem-
perature for which 50% of the protein is unfolded.
Surface plasmon resonance measurement and analysis. Surface plasmon
resonance experiments were conducted at 25 °C on the BIAcore 3000 instrument
with TBS buffer (10 mM Tris-HCl, pH 8, 150 mM NaCl, and 0.005% surfactant
P20). TBS buffer was supplemented with 1% BSA to prevent non-speciﬁc binding.
The human TCR-speciﬁc monoclonal antibody, 12H8 antibody68, was coupled to
research-grade CM5 chips with standard amine coupling. The experiment was
conducted with one empty ﬂow cell (use for subtraction as blank) and one ﬂow cell
with the EM2 TCR captured to approximately 300 response unit per ﬂow cell onto
the 12H8 antibody68. Then a concentration range of 200 µM maximum of the
pHLA complexes were passed over all the ﬂow cells. The ﬁnal response was cal-
culated by subtracting the response of the antibody alone and that of EM2 TCR.
BIAevaluation Version 3.1 was used for data analysis using the 1:1 Langmuir
binding model. Experiments were carried out in duplicate (n= 2).
Statistical analyses. All statistical analyses were undertaken using Prism 6
(GraphPad, CA, USA). A Dunnett's two-way analysis of variance was used for all
non-parametric non-paired analysis where multiple comparisons were made.
Statistical signiﬁcance was deﬁned as *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
Data availability
Coordinates submitted to PDB database, and the PDB codes are 6MT6 (HLA-
B*37:01-NP338), 6MT4 (HLA-B*37:01-NP338-L7S), 6MT5 (HLA-B*37:01-NP338-
V6L), 6MTL (HLA-B*44:05-NP338), 6MT3 (HLA-B*18:01-NP338), and 6MTM
(EM2 TCR-HLA-B*37:01-NP338). All other data that support the ﬁndings of this
study are available from the corresponding author upon reasonable request. A
reporting summary for this article is available as a Supplementary Information ﬁle.
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